Wedbush Has Negative Forecast for HOWL FY2025 Earnings

Werewolf Therapeutics, Inc. (NASDAQ:HOWL) – Wedbush reduced their FY2025 earnings estimates for Werewolf Therapeutics in a research report issued to clients and investors on Wednesday, March 12th. Wedbush analyst R. Driscoll now expects that the company will earn ($1.84) per share for the year, down from their previous forecast of ($0.97). Wedbush has a “Outperform” rating and a $8.00 price target on the stock. The consensus estimate for Werewolf Therapeutics’ current full-year earnings is ($1.56) per share. Wedbush also issued estimates for Werewolf Therapeutics’ FY2026 earnings at ($1.13) EPS, FY2027 earnings at ($1.57) EPS, FY2028 earnings at ($1.63) EPS and FY2029 earnings at ($0.63) EPS.

Several other equities research analysts have also commented on HOWL. JMP Securities dropped their price target on shares of Werewolf Therapeutics from $12.00 to $4.00 and set a “market outperform” rating on the stock in a research note on Tuesday, January 14th. HC Wainwright restated a “buy” rating and issued a $15.00 price target on shares of Werewolf Therapeutics in a research note on Wednesday, March 12th.

Werewolf Therapeutics Price Performance

HOWL opened at $1.17 on Monday. The firm has a market cap of $52.45 million, a price-to-earnings ratio of -0.76 and a beta of 0.37. Werewolf Therapeutics has a fifty-two week low of $1.03 and a fifty-two week high of $6.89. The company’s 50-day moving average price is $1.34 and its 200 day moving average price is $1.79. The company has a quick ratio of 10.10, a current ratio of 10.10 and a debt-to-equity ratio of 0.29.

Werewolf Therapeutics (NASDAQ:HOWL) last released its quarterly earnings data on Tuesday, March 11th. The company reported ($0.46) earnings per share for the quarter, missing the consensus estimate of ($0.43) by ($0.03). Werewolf Therapeutics had a negative return on equity of 58.83% and a negative net margin of 578.80%.

Institutional Investors Weigh In On Werewolf Therapeutics

Several large investors have recently made changes to their positions in the company. PFM Health Sciences LP boosted its holdings in shares of Werewolf Therapeutics by 4.9% in the third quarter. PFM Health Sciences LP now owns 3,398,747 shares of the company’s stock valued at $7,205,000 after acquiring an additional 157,673 shares in the last quarter. Geode Capital Management LLC boosted its holdings in shares of Werewolf Therapeutics by 2.4% in the fourth quarter. Geode Capital Management LLC now owns 702,558 shares of the company’s stock valued at $1,040,000 after acquiring an additional 16,569 shares in the last quarter. State Street Corp boosted its holdings in shares of Werewolf Therapeutics by 12.4% in the third quarter. State Street Corp now owns 476,439 shares of the company’s stock valued at $1,010,000 after acquiring an additional 52,528 shares in the last quarter. Northern Trust Corp boosted its holdings in shares of Werewolf Therapeutics by 7.3% in the fourth quarter. Northern Trust Corp now owns 244,390 shares of the company’s stock valued at $362,000 after acquiring an additional 16,640 shares in the last quarter. Finally, Bridgeway Capital Management LLC boosted its holdings in shares of Werewolf Therapeutics by 24.4% in the fourth quarter. Bridgeway Capital Management LLC now owns 109,586 shares of the company’s stock valued at $162,000 after acquiring an additional 21,500 shares in the last quarter. Institutional investors and hedge funds own 64.84% of the company’s stock.

Werewolf Therapeutics Company Profile

Werewolf Therapeutics, Inc, a biopharmaceutical company, develops therapeutics engineered to stimulate the body's immune system for the treatment of cancer. The company, through its proprietary PREDATOR platform, designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies.